CompletedNot Applicable

Ampholipad Real-World Data in Taiwan

Taiwan102 participantsStarted 2018-09-09

Plain-language summary

A retrospective, post-marketing, multi-center chart review study includes patients who had been prescribed Ampholipad.

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or female ≥ 2 years of age
✓. Patients who had received at least one dose of Ampholipad treatment, with available baseline serum creatinine (SCr) data within 1 month prior to first Ampholipad use and at least one post baseline SCr data during treatment period

✕. Patients whose medical chart cannot provide both the start and stop dates of Ampholipad for a course of treatment (first course only)
✕. Patients who had documented HIV infection diagnosis
✕. Patients with potential end-stage renal disease (ESRD) receiving regular dialysis within 1 month prior to first Ampholipad use

Incidence of nephrotoxicity

Timeframe: Ampholipad treatment course, up to 42 days

NCT IDNCT03641131

SponsorTaiwan Liposome Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-01-02